Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared H. Jack West’s post on X, adding:
“Appreciate Jack’s perspective.
B/c SBRT usually low toxicity and convenient, we see how PFS translates into meaningful benefits – time off systemic, less treatment burden.
But agree trials should directly test improvements in pt-centered endpts vs relying on radiographic PFS surrogate.”
H. Jack West, Vice President of Clinical Development at Summit Therapeutics, Inc., shared a post on X:
“People rightfully debate the importance of PFS vs. OS in general, but I would contend that PFS endpoint is definitely aiming low when local therapy is used for OMD — you are eradicating most expected site of PD.
I’ve become a believer in local Rx for OMD overall, but non-rad oncs are going to be rightfully skeptical until OMD studies aim higher than the ‘layup’ of showing PFS benefit from local Rx.”
More posts featuring Nina Niu Sanford.